Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Laurence Rahme
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Spero Therapeutics, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Rahme is a co-founder of Spero Therapeutics, Inc. and holds equity in the private company. Spero Therapeutics develops therapies for the treatment of persistent bacterial infections. The research project seeks to uncover host mechanisms that permit persistent bacterial infections and to test the potential of a novel compound against such infections. The results of the research could therefore be of interest to the company. The Partners Committee on Outside Activities review panel evaluated the financial interest in connection with this research project and determined that, based on the close connection between the company's interests and the research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Molecular and Metabolic inter-kingdom actions of a bacterial quorum sensing signal in promotion of host tolerance/resilience.
The ability of humans to tolerate persistent infections that pose serious challenges, especially in patients whose immune system is compromised, is not well understood. No drugs are currently available against persistent infections. Our study proposes to uncover host mechanisms that permit persistent bacterial infections and test the potential of a novel compound against such infections.
Filed on January 02, 2018.
Tell us what you know about Laurence Rahme's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Laurence Rahme filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Laurence Rahme | Massachusetts General Hospital | Conflict of Interest | Spero Therapeutics, Inc. | $10,000 - $19,999 |
| Laurence Rahme | Massachusetts General Hospital | Conflict of Interest | Spero Therapeutics, In. | $10,000 - $19,999 |
| Laurence Rahme | Massachusetts General Hospital | Conflict of Interest | Spero Therapeutics, Inc. | Value cannot be readily determined |
| Laurence Rahme | Massachusetts General Hospital | Conflict of Interest | Spero Therapeutics, In. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.